Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ophthalmopathy Clear all
Completed Not applicable Interventional Results available

Bifocal Lenses In Nearsighted Kids

NCT02255474
View directory record Official record
Conditions
Refractive Errors
Interventions
Biofinity Multifocal D +1.50 add, Biofinity Multifocal D +2.50 add, Biofinity
Device
Lead sponsor
Ohio State University
Other
Eligibility
7 Years to 11 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 23, 2026, 8:19 AM EDT
Completed No phase listed Observational

Telemedicine Approaches to Evaluating Acute-phase ROP

NCT01264276
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
32 Weeks to 40 Weeks
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
11
States / cities
Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 4 Interventional Results available

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

NCT02689518
View directory record Official record
Conditions
Macular Degeneration, Wet Macular Degeneration
Interventions
Intravitreal aflibercept injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Not applicable Interventional

Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery

NCT00406913
View directory record Official record
Conditions
Endophthalmitis, Cataract Surgery, Prophylaxis
Interventions
mupirocin ointment, SOC sterilization
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 23, 2026, 8:19 AM EDT
Completed No phase listed Observational

Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia

NCT00265590
View directory record Official record
Conditions
Aniridia
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 1 Interventional Results available

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

NCT02848313
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Elamipretide
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

NCT07780890
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG), Dry Eye Disease (DED), Keratoconus, Lasik Eye Surgery
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 79 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting Phase 3 Interventional

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib, Primary Local Therapy
Drug · Procedure
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
35
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional

CMV Retinitis Retreatment Trial

NCT00000766
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 23, 2026, 8:19 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants

NCT05992922
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
IC265 Ophthalmic Solution 1%, Placebo Ophthalmic Solution (Vehicle)
Drug
Lead sponsor
Iacta Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 23, 2026, 8:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measuring Corneal Cells With Specular Microscopy

NCT01792154
View directory record Official record
Conditions
Retinal Diseases
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 23, 2026, 8:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Annular Array Ultrasound in Ophthalmology

NCT01415037
View directory record Official record
Conditions
Posterior Vitreous Detachment, Diabetic Retinopathy
Interventions
annular array ultrasound exam
Procedure
Lead sponsor
Columbia University
Other
Eligibility
60 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional

Lutein for Age-Related Macular Degeneration

NCT00006202
View directory record Official record
Conditions
Macular Degeneration
Interventions
Lutein
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 23, 2026, 8:19 AM EDT
Completed No phase listed Observational

Restricted Useful Field View as a Risk Factor in Older Adults

NCT00013351
View directory record Official record
Conditions
Vision Impairment
Interventions
Prevention of Falls
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting No phase listed Observational

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

NCT07144137
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Complement Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Mountain View, California • Oak Forest, Illinois • Carmel, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes

NCT03846453
View directory record Official record
Conditions
Dry Eye
Interventions
HL036 Ophthalmic Solution, Placebo
Biological
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Phoenix, Arizona • Newport Beach, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

NCT02401945
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
DE-120, Aflibercept
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

NCT00089063
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
tyrosinase peptide, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, Montanide ISA 51 VG, sargramostim, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Visual Remapping to Aid Reading With Field Loss

NCT03848663
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Traditional Remapping, Personalized Remapping
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

NCT04469998
View directory record Official record
Conditions
Posterior Blepharitis, Meibomian Gland Dysfunction
Interventions
AXR-270 Low Dose, AXR-270 High Dose, AXR-270 Vehicle
Drug
Lead sponsor
AxeroVision, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

NCT05270863
View directory record Official record
Conditions
Presbyopia
Interventions
BRIMOCHOL™ PF, Carbachol PF, Brimonidine tartrate
Drug
Lead sponsor
Visus Therapeutics
Other
Eligibility
45 Years to 80 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
15
States / cities
Glendale, California • Rancho Cordova, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 4 Interventional Results available

Using Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery

NCT04701593
View directory record Official record
Conditions
Retinal Detachment
Interventions
Triamcinolone Acetonide 40mg/mL
Drug
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
19 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 23, 2026, 8:19 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Tears Substitutions and Their Effects on Higher Order Aberrometery

NCT00812721
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Preservative Free Saline, Optive, Refresh Moderate/Severe, Systane, Systane Ultra
Other
Lead sponsor
Gina Rogers
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 23, 2026, 8:19 AM EDT
Completed No phase listed Observational

Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration

NCT02941263
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 23, 2026, 8:19 AM EDT